October 10
10:30 am - 11:15 am EDT

LOCAL TIME

Structural biology is advancing biotherapeutics design

Experimental structural biology tools such as X-ray Crystallography (XRC) and Cryo-Electron microscopy (Cryo-EM) are providing the basis for a revolution in biotherapeutics design. This webinar delves into the use and history of XRC and Cryo-EM in biotherapeutics research, highlighting how their use is advancing the understanding and rational design of biologics. It also explores how this research conducted over the past decades, is enabling current and future AI/ML technologies with the capability of providing the biotherapeutics engineer the means to accelerate the design and development of novel next generation biotherapeutics.

The Webinar is targeted at those working in Biotherapeutics research, interested in learning about structural biology and computational techniques, covering:

  • Macromolecular XRC, its coevolution with Biotherapeutics research and how it provides insight, understanding and design capabilities for biologics
  • The Cryo-EM "Resolution Revolution" and how the technique is pushing the boundaries of biotherapeutics structural biology
  • The rapid advancements of AI/ML in protein structural and their potential for transformative impact on structural biology and biologics design

register now
register for the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Glen Spraggon

Glen Spraggon

Exec. Director, Structure Bioinformatics & Data Science, Biologics Research Center, Novartis Biomedical Research San Diego

Glen obtained his D. Phil in Molecular Biophysics from the University of Oxford. He subsequently conducted postdoctoral research at the University of California San Diego, contributing to the unraveling of the molecular basis of fibrinogen polymerization. He then joined the Genomics Institute of the Novartis Research Foundation (GNF) to develop computational, engineering, and experimental methodologies for high throughput structure determination using macromolecular crystallography. During his time at GNF, Glen advanced to the position of Director of Structure-Based Discovery, with a particular focus on integrating and applying experimental and computational methods to structure-based design, especially in relation to biologics. Currently, Glen serves as an Executive Director at Novartis Biomedical Research San Diego in the Biologics Research Center, where he leads a global group called Structure, Bioinformatics, and Data Science. This group is dedicated to applying structure and computational techniques to the development of innovative biotherapeutics.

Sy Mukherjee
moderator

Sy Mukherjee

Freelance healthcare journalist

Sy Mukherjee is a veteran healthcare journalist who has been covering the space with a focus on biopharma, drug development, digital health, and the intersection of medicine and technology across the health industry for more than a decade. He has served roles as: the first editor of the industry trade publication BioPharma Dive; a biopharma/digital health/healthcare-specialized reporter at Fortune Magazine for nearly six years, where he authored a biopharma/digital health newsletter, wrote articles for Fortune.com, and reported for the print magazine issue (including two cover stories focused on the digital health revolution and the intersection of data, biology, and health systems), and helped plan, cover, and moderate events at the annual Brainstorm Health conference. Additionally, he served as a consultant at the boutique path-to-market strategy life sciences consultancy IDEA Pharma, focusing on stakeholder-oriented strategic communications for biotech and pharma clients.

Sy has extensive experience moderating webinars and panels at both small and high-profile venues, including panels at Fortune Brainstorm Health and the Biden Cancer Summit. He is currently an independent and freelance journalist still focused on the same space that he's covered for his entire career.